Viracta Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview

Viracta Therapeutics

04/11/2022 17:49

* Viracta Therapeutics Inc  VIRX.OQ   VIRX.O  is expected
to show
no change in quarterly revenue when it reports  results on
November 8 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Viracta
Therapeutics Inc
is for a loss of 30 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Viracta
Therapeutics Inc is $15​, above​ its last closing price
of $4.35. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.30       -0.30      -0.28     Beat    5.9
 Mar. 31 2022  -0.31       -0.31      -0.28     Beat    11.1
 Dec. 31 2021  -0.43       -0.43      -0.31     Beat    28.7​
 Sep. 30 2021  -0.30       -0.31      -0.40     Missed  -29
 ​​Jun.        -0.24       -0.24      -0.25     Missed  -5.6
 30 2021                                                
 Mar. 31 2021  0.03        -0.21      0.35      Beat    266.7​
 Dec. 31 2020  -0.96       -0.96      -0.73     Beat    23.6
 Sep. 30 2020  -1.21       -1.18      -1.01     Beat    13.9
 This summary was machine generated November 4 at 17:49 GMT.  All
figures in US dollars  unless otherwise stated